Latest KFF Health News Stories
Journalists Discuss African Mpox Upsurge, EpiPen Alternative, and Medicaid Unwinding
KFF Health News and California Healthline staff made the rounds on national and state media this week to discuss topical stories. Here’s a collection of their appearances.
The FDA Calls Them ‘Recalls,’ Yet the Targeted Medical Devices Often Remain in Use
With medical devices, recalls are not always what they seem. In some recalls, including some of the most serious, the FDA and the manufacturers let doctors and hospitals continue to use the devices.
Inside Project 2025: Former Trump Official Outlines Hard Right Turn Against Abortion
Former President Donald Trump has distanced himself from a Heritage Foundation document that outlines positions on abortion and a range of other social issues. But Democrats view it as a window into the far right’s to-do list and a clear opening for political attack.
The CDC’s Test for Bird Flu Works, but It Has Issues
The Centers for Disease Control and Prevention promises better tests are being developed, but the episode points to vulnerabilities in the country’s defense against emerging outbreaks.
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
Qué son los medicamentos compuestos que millones de personas usan para bajar de peso
La FDA permite e incluso fomenta que las farmacias de compuestos produzcan y vendan copias cuando un medicamento está en escasez, como es el caso de las drogas para combatir el sobrepeso y la obesidad.
From Dr. Oz to Heart Valves: A Tiny Device Charted a Contentious Path Through the FDA
The story of MitraClip, a device Dr. Oz helped invent to treat faulty heart valves, is a cautionary tale about the science, business, and regulation of medical technology.
KFF Health News' 'What the Health?': SCOTUS Term Wraps With a Bang
The Supreme Court has issued its final opinions for the 2023-24 term, including decisions affecting abortion access, the opioid epidemic, and how the federal government functions. In this special episode, Sarah Somers , legal director of the National Health Law Program, joins KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss how the justices disposed of the term’s health-related cases and what those decisions could mean going forward.
The Supreme Court Just Limited Federal Power. Health Care Is Feeling the Shockwaves.
A Supreme Court ruling restricting federal power will likely have seismic ramifications for health policy. A flood of litigation — with plaintiffs like small businesses, drugmakers, and hospitals challenging regulations they say are too expensive or burdensome and not authorized by law — could leave the country with a patchwork of disparate health regulations.
KFF Health News' 'What the Health?': SCOTUS Ruling Strips Power From Federal Health Agencies
In what will certainly be remembered as a landmark decision, the Supreme Court has overruled a 40-year-old precedent that gave federal agencies, rather than judges, the power to interpret ambiguous laws passed by Congress. Administrative experts say the decision will dramatically change the way key health agencies do business. Also, the court decided not to decide whether a federal law requiring hospitals to provide emergency care overrides Idaho’s near-total ban on abortion. Alice Miranda Ollstein of Politico, Victoria Knight of Axios, and Joanne Kenen of Johns Hopkins University and Politico Magazine join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
KFF Health News' 'What the Health?': SCOTUS Rejects Abortion Pill Challenge — For Now
The Supreme Court has dismissed a challenge to the FDA’s approval of the abortion pill mifepristone, ruling unanimously that the anti-abortion doctor group that filed the suit lacked standing. But abortion opponents are expected to pursue other strategies to ban or restrict the medication. Meanwhile, the Biden administration moves to stop the inclusion of medical debt on individual credit reports, and former President Donald Trump tries to claim credit for $35 insulin. Anna Edney of Bloomberg News, Rachana Pradhan of KFF Health News, and Emmarie Huetteman of KFF Health News join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF president and CEO Drew Altman about KFF’s new “Health Policy 101” primer.
KFF Health News' 'What the Health?': Nursing Home Staffing Rules Prompt Pushback
The nursing home industry — as well as a healthy number of Congress members — are all pushing back on the Biden administration’s new rules on nursing home staffing. Industry officials say that there are not enough workers to meet the requirements and that the costs would be prohibitive. Meanwhile, Democrats on Capitol Hill are trying to force Republicans to explain their exact positions on assuring access to contraceptives and in vitro fertilization. Rachel Cohrs Zhang of Stat, Alice Miranda Ollstein of Politico, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF Health News’ Bram Sable-Smith, who reported and wrote the latest KFF Health News-NPR “Bill of the Month” feature about a free cruise that turned out to be anything but.
KFF Health News' 'What the Health?': Waiting for SCOTUS
June is when the Supreme Court typically issues rulings in the major cases it hears during that year’s term. This year, those interested in health policy are awaiting decisions in two abortion-related cases and one that could reshuffle the way health policies (and all other federal policies) are made. In this special episode, KFF’s Laurie Sobel, associate director for women’s health policy, joins Julie Rovner for a review of the cases and a preview of how the court might rule.
Psychoactive Drugs Are Having a Moment. The FDA Will Soon Weigh In.
Mounting evidence suggests psychoactive drugs including LSD, ketamine, mushrooms, and MDMA can be powerful treatments for severe depression and PTSD. But not everyone is convinced. And even if such drugs gain FDA approval, safety protocols could render them extremely expensive.
FDA Urged To Relax Decades-Old Tissue Donation Restrictions for Gay and Bisexual Men
Federal regulations prevent gay and bisexual men from donating tissue, such as corneas, ligaments, and blood vessels. Similar restrictions have been relaxed or lifted for donated blood and organs in recent years.
Reclaman revisar viejas restricciones que previenen que hombres gay y bisexuales donen tejidos
Defensores piden que las pautas para los tejidos donados por hombres gays y bisexuales sean las mismas que aplican al resto del cuerpo humano.
FDA Said It Never Inspected Dental Lab That Made Controversial AGGA Device
Johns Dental Laboratories stopped making the Anterior Growth Guidance Appliance last year after a KFF Health News-CBS News investigation into allegations of patient harm. The company had “never” reported any complaints about its products to the FDA, according to the agency.
Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge
The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.
What’s Keeping the US From Allowing Better Sunscreens?
A decade after Congress told the FDA to expedite the approval of more effective sunscreens, the federal government still has not approved sunscreen ingredients that are safely being used around the world. Meanwhile, skin cancer is the nation’s most common cancer.
Las pruebas han detectado el virus en el ganado en nueve estados, principalmente en Texas y Nuevo México, y más recientemente en Colorado. Una persona ha dado positivo para el H5N1.
